Year on year revenues up 'significantly' at Avacta
24th August 2012
AVACTA Group has seen sales of its key Optim product grow by 50% and has extended a commercial partnership into South East Asia.
The Optim analytical instrument is aimed at helping companies reduce the risks and expense associated with biological drug development.
Wetherby-based healthcare technology firm Avacta, which is listed on the Alternative Investment Market, distributes Optim through several companies, including Pall Life Sciences.
In a trading update this morning, Avacta said Pall was now distibuting ......for the full story register now for free or login below...
More News News Archive
- Register Now For Free!